# Identification of Patients at Elevated Cancer Risk through a Community-Based Genetic Testing Program

**Authors:** Danielle Brabender, Emily Siegel, Julie O. Culver, Jacob G. Comeaux, Anjali Date, Amanda Woodworth

PMC · DOI: 10.1245/s10434-025-17820-w · Annals of Surgical Oncology · 2025-08-06

## TL;DR

A community-based genetic testing program identified many women at higher cancer risk who might not have been tested otherwise.

## Contribution

The study demonstrates the effectiveness of community-based genetic testing in identifying cancer risks beyond standard guidelines.

## Key findings

- 7.6% of tested women had pathogenic/likely pathogenic genetic variants in 18 different genes.
- Over 5% of the total population needed changes in cancer screening or risk-reducing procedures.
- CHEK2 and MUTYH were the most commonly identified high-risk genes.

## Abstract

Only a subset of individuals meeting National Comprehensive Cancer Network (NCCN) guidelines for genetic screening of hereditary cancers are being offered testing. A community-based screening program has the potential to expand access, identify critical screening opportunities among those testing positive, and have potential downstream clinical effects.

We conducted a retrospective review of women who underwent mammography and genetic testing at a community hospital between August 2020 and May 2023. For those testing positive for a pathogenic/likely pathogenic (P/LP) variant, potential cancer screening and surgical recommendations were identified utilizing NCCN guidelines.

A total of 14,192 women were screened, with 3224 (23%) meeting NCCN criteria. Of these patients, 50.3% opted for testing and 7.6% were found to have P/LP variants, encompassing 18 different genes. The genes with the highest prevalence of P/PV variants included CHEK2 (26%), MUTYH (21%), BRCA2 (8%), APC I1370K (8%), and Lynch Syndrome-associated (7%). Among those positive for a P/LP variant, individuals were identified to be at an increased risk for at least one form of cancer, including breast (52%), colon (45%), ovarian (31%), pancreas (28%), melanoma (20%), endometrial (11%), urologic (7%), and stomach/small bowel (7%), leading to a potential change in screening and risk-reducing surgery recommendations. For the total population tested, 5.3% of women qualified for MRI or earlier mammograms, and 3.4% needed earlier or more frequent screening colonoscopies.

These findings suggest that a community-based genetic program can identify individuals at increased cancer risk who might otherwise remain undetected. These results provide opportunities to reduce morbidity/mortality through increased screening and risk-reducing procedures.

## Linked entities

- **Genes:** CHEK2 (checkpoint kinase 2) [NCBI Gene 11200], MUTYH (mutY DNA glycosylase) [NCBI Gene 4595], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675]
- **Diseases:** breast cancer (MONDO:0004989), colon cancer (MONDO:0002032), ovarian cancer (MONDO:0005140), pancreatic cancer (MONDO:0005192), melanoma (MONDO:0005105), endometrial cancer (MONDO:0002447)

## Full-text entities

- **Genes:** MUTYH (mutY DNA glycosylase) [NCBI Gene 4595] {aka MYH}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, CHEK2 (checkpoint kinase 2) [NCBI Gene 11200] {aka CDS1, CHK2, HuCds1, LFS2, PP1425, RAD53}
- **Diseases:** hereditary cancers (MESH:D009386), Lynch Syndrome-associated (MESH:D003123), Cancer (MESH:D009369), P/PV (MESH:D011087), melanoma (MESH:D008545)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** I1370K

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12534363/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12534363/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC12534363/full.md

---
Source: https://tomesphere.com/paper/PMC12534363